The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

Authors :: Parving, Hans-Henrik
Lehnert, Hendrik
Brochner-Mortensen, Jens
Gomis, Ramon
Andersen, Steen
Arner, Peter
Source :: The New England Journal of Medicine. Sept 20, 2001, Vol. 345 Issue 12, p870, 9 p.
Publication Year :: 2001
Abstract: The antihypertensive drug Avapro can slow the progression of kidney disease in people with type 2 diabetes and high blood pressure, according to a study of 590 patients. Avapro belongs to a new class of drugs called angiotensin II-receptor blockers.

Subjects :: Bristol-Myers Squibb Co. -- Product information
Avapro (Medication) -- Evaluation
Diabetic nephropathies -- Prevention
Type 2 diabetes -- Complications
Angiotensin II receptor blockers -- Evaluation

Tools